<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Screening and diagnostic testing for HIV infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Screening and diagnostic testing for HIV infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Screening and diagnostic testing for HIV infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 27, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nearly 15 percent of HIV-infected persons in the United States remain unaware of their HIV infection, leading to significant morbidity and the risk of further transmission to others. Improved access to HIV testing and new testing algorithms can decrease the number of individuals who present with advanced immunocompromise, enhance the detection of newly infected individuals, and reduce transmission to others.</p><p>This topic will address screening and diagnostic testing for HIV infection in adults in clinical care settings. Detailed information about screening for HIV in the blood supply, the diagnosis of HIV infection in children, and the diagnosis of HIV infections in patients presenting with symptoms of acute infection are found elsewhere. (See  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'Infectious disease screening and surveillance'</a> and  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months"</a> and  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3909323191"><span class="h1">WHOM TO TEST</span><span class="headingEndMark"> — </span>HIV testing should be performed to diagnose HIV in patients with clinical signs and symptoms of acute or chronic infection as well as those with a possible exposure to HIV. HIV testing should also be incorporated into routine screening of healthy individuals, including pregnant women.</p><p class="headingAnchor" id="H3198185622"><span class="h2">Symptoms of HIV infection</span><span class="headingEndMark"> — </span>All patients with signs and symptoms of acute or chronic HIV infection should be tested. For patients presenting with clinical manifestations of acute HIV infection, testing for HIV RNA may be needed. A detailed discussion of the clinical manifestations of HIV infection is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H466086220"><span class="h2">Possible HIV exposure</span><span class="headingEndMark"> — </span>Patients who present after a known high-risk exposure to HIV (eg, sexual or percutaneous) should be tested for HIV infection and assessed for post-exposure antiretroviral therapy (ART). Such patients should then have follow-up testing over the course of four to six months (depending upon the type of test that is used). Topic reviews that discuss risk factors for HIV transmission and the use of post-exposure prophylaxis are found elsewhere. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Risk factors for infection'</a> and  <a class="medical medical_review" href="/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults"</a> and  <a class="medical medical_review" href="/d/html/3764.html" rel="external">"Management of health care personnel exposed to HIV"</a>.)</p><p>HIV testing is also indicated for the following groups who are at high risk for exposure to HIV:</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who seek screening for sexually transmitted infections [<a href="#rid1">1</a>]. This provides an opportunity for risk reduction education as well as diagnosis of HIV infection. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are considering pre-exposure antiretroviral prophylaxis as an HIV prevention strategy. For such patients, HIV testing should be performed prior to starting pre-exposure prophylaxis and every three months thereafter. Pre-exposure prophylaxis is discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p></p><p class="headingAnchor" id="H1254169412"><span class="h2">Routine screening</span><span class="headingEndMark"> — </span>For patients without risk factors for HIV infection, we recommend at least one-time HIV screening in adults and adolescents 13 to 75 years of age. In addition, pregnant women should be tested for HIV early in each pregnancy using an "opt-out" approach, even if they have been screened during previous pregnancies. (See  <a class="medical medical_review" href="/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'HIV'</a> and <a class="local">'Consent'</a> below.)</p><p>Although one-time testing at a routine medical clinic visit is reasonable for most patients, annual or more frequent testing is recommended for high-risk persons including:</p><p class="bulletIndent1"><span class="glyph">●</span>Men who have sex with men (MSM) with sexual partners who are HIV-infected or have unknown serostatus. The Centers for Disease Control and Prevention (CDC) notes that sexually active MSM may benefit from testing every three to six months [<a href="#rid2">2,3</a>]. Frequent testing is particularly important for MSM aged 13 to 24 years, where the rate of new infections increased by 43 percent from 2003 to 2014 [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Injection-drug users.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persons who exchange sex for money or drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex partners of persons who are HIV-infected, bisexual, or inject drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persons who have sex with partners whose HIV status is unknown.</p><p></p><p>The importance of repeat testing among those at ongoing risk is supported by findings from the CDC National HIV Surveillance System [<a href="#rid5">5</a>]. Between 2006 and 2009, there were an estimated 125,104 new diagnoses of HIV infection. For those with a detailed testing history, 41 percent were diagnosed on their first test, while 59 percent were diagnosed with HIV infection within one to two years after a negative test result. </p><p>The use of routine HIV testing in resource-limited settings is discussed below. (See <a class="local">'Resource-limited settings'</a> below.)</p><p class="headingAnchor" id="H384998360"><span class="h3">Rationale for routine screening</span><span class="headingEndMark"> — </span>Identifying patients infected with HIV is important because it allows:</p><p class="bulletIndent1"><span class="glyph">●</span>The institution of early ART, which reduces clinical events and mortality in patients with HIV infection [<a href="#rid6">6-9</a>]. In the United States, patients who are diagnosed early in the course of infection and are successfully treated with ART may have life expectancies similar to those in the general population [<a href="#rid10">10,11</a>]. However, in 2008, 33 percent of patients were diagnosed late in the course of infection and developed AIDS within one year of their initial HIV diagnosis [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate preventive care (eg, immunizations and prophylactic antibiotics) [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced HIV transmission to others through reductions in viral load secondary to ART, and changes in HIV risk behaviors [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Risk factors for infection'</a>.)</p><p></p><p>Despite the importance of early diagnosis, a substantial number of individuals remain unaware that they are infected with HIV. In 2015, the World Health Organization (WHO) reported that only 54 percent of people with HIV infection knew their HIV status worldwide [<a href="#rid16">16</a>]. In the United States, an estimated 1.1 million persons were living with HIV in 2015, and nearly 15 percent had undiagnosed infections [<a href="#rid17">17</a>].</p><p>The percentage of persons with undiagnosed HIV infection varies by age and geographic area. As an example, in the United States, the highest percentage of undiagnosed infections was in persons aged 13 to 24 years (51 percent), followed by persons aged 25 to 34 years (28 percent). With regards to geographic area, the percentage of individuals with undiagnosed HIV infection at the end of 2012 was greater in Louisiana (approximately 23 percent) compared with &lt;10 percent in Colorado, Connecticut, Delaware, Hawaii, and New York [<a href="#rid18">18</a>].</p><p>In a national survey, in which 28,462 individuals at high risk for acquiring HIV (MSM and persons who inject drugs) were anonymously interviewed and screened for HIV infection, approximately 13 percent tested positive for HIV, and 9 percent were unaware of their diagnosis [<a href="#rid19">19</a>]. Of those 335 individuals who were unaware of their diagnosis, approximately 70 percent had seen a clinician in the prior year, but less than half had been offered HIV testing. </p><p>In the United States, the CDC issued guidelines in 2006 advocating routine voluntary HIV screening of all patients aged 13 to 64 years as a normal part of medical care, without the need for signed consent or counseling [<a href="#rid20">20</a>]. Prior to that, risk-based screening had been the standard of care. The use of routine screening was introduced, in part, to identify patients who may not disclose their risk factors or see themselves at risk. In addition, risk assessment can be time consuming, and providers may not be able to reliably integrate risk assessment into routine care. As an example, in a study of 440 HIV-infected patients, of whom the majority had a CD4 count &lt;350 cells/microL at the time of diagnosis, only 26 percent had HIV risk factors documented in the medical record more than one year before their diagnosis [<a href="#rid21">21</a>].</p><p>The American College of Physicians (ACP) Guidance Statement on HIV screening, released in 2009, similarly endorsed universal screening, although it suggested that the age range be expanded to 75 years because of the growing number of HIV infections in older patients [<a href="#rid22">22</a>]. In 2013, the US Preventive Services Task Force (USPSTF) recommended universal HIV screening among patients aged 15 to 65 years and all pregnant persons [<a href="#rid23">23</a>]. This recommendation was reaffirmed in 2019 [<a href="#rid24">24</a>]. The USPSTF also recommends that HIV screening be offered to younger adolescents and older adults who are at increased risk for infection. This includes MSM and active injection drug users, as well as those who have acquired or requested testing for sexually transmitted infections, have anal intercourse without a condom, have vaginal intercourse without a condom with more than one partner whose HIV status is unknown, have transactional sex (exchanges sex for drugs or money), and/or have a sex partner who is living with HIV or is in a high-risk category [<a href="#rid24">24</a>].</p><p>Multiple studies have indicated that routine HIV testing is cost effective in the United States, especially if the seroprevalence is ≥0.1 percent (national average of 0.5 percent) [<a href="#rid25">25-31</a>]. In addition, the use of universal rather than targeted testing in ambulatory care settings appears to increase the number of new HIV diagnoses and reduce the proportion diagnosed late in the course of disease [<a href="#rid32">32-36</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A cluster randomized trial in the United Kingdom compared an educational intervention promoting opt-out rapid HIV testing versus standard of care in community-based clinics where the HIV prevalence was high (8 patients per 1000 adults) [<a href="#rid33">33</a>]. Over approximately two years, there were more patients diagnosed with HIV in the practices that received the intervention (32 versus 14). In addition, there was a nonsignificant increase in the mean CD4 count at the time of diagnosis (356 versus 270 cells/microL). However, three clinics in the intervention arm withdrew (one because of workload reasons).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-center cluster randomized trial compared universal and targeted HIV screening in an urban emergency department [<a href="#rid32">32</a>]. The estimated seroprevalence was 0.36 percent. When universal screening was performed, 1915 of 4692 patients (41 percent) consented and six new HIV infections were diagnosed. When targeted screening was performed, 1813 of 4880 (37 percent) had no testing indication; of the 3067 remaining patients, 47 percent consented and three patients were diagnosed with HIV.</p><p></p><p class="headingAnchor" id="H2842890537"><span class="h1">TESTING ALGORITHM</span></p><p class="headingAnchor" id="H2898308609"><span class="h2">Preferred approach</span><span class="headingEndMark"> — </span>Our preferred testing algorithm uses a fourth-generation antigen/antibody combination HIV-1/2 immunoassay plus a confirmatory HIV-1/HIV-2 antibody differentiation immunoassay  (<a class="graphic graphic_algorithm graphicRef91270" href="/d/graphic/91270.html" rel="external">algorithm 1</a>). A discussion of the different types of tests is found below. (See <a class="local">'Tests'</a> below.)</p><p>For HIV screening of asymptomatic individuals or patients with signs and symptoms of chronic infection, a fourth-generation combination HIV-1/2 immunoassay is initially performed. This assay detects both HIV-1 and HIV-2 antibodies as well as HIV P24 antigen. Whenever possible, we use the combination tests designed only for laboratory use, rather than the rapid lateral flow assay, because of increased sensitivity. (See <a class="local">'Combination HIV antigen and antibody tests'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>If the fourth-generation combination assay is negative, the person is considered HIV-uninfected, and no further testing needs to be done.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fourth-generation combination assay is positive, an HIV-1/HIV-2 antibody differentiation immunoassay is performed. This test confirms the results of the combination assay and also provides information as to whether the patient is infected with HIV-1, HIV-2, or both viruses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A plasma HIV RNA level should be obtained to evaluate for acute infection if the fourth-generation test is positive and the confirmatory HIV-1/HIV-2 antibody differentiation immunoassay is indeterminate or negative. (See <a class="local">'Indeterminate test results'</a> below.)</p><p></p><p>If there is concern for acute HIV infection (eg, the patient presents with mononucleosis-like symptoms and had a recent high-risk exposure), additional testing with HIV RNA (either qualitative or quantitative) should be performed. A detailed discussion of how to diagnose acute HIV infection is found elsewhere. (See  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p>Our approach to HIV testing is based upon the recommendations from the Centers for Disease Control and Prevention (CDC) [<a href="#rid37">37</a>]. The rationale for the use of this algorithm is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The combination antigen/antibody tests are better able to identify acute/early infection compared with antibody-only tests, since they can detect HIV p24 antigen when antibody may not yet be present (eg, "window period of acute HIV infection") [<a href="#rid38">38</a>]. Early detection is important because of the high risk of transmission that precedes seroconversion and the potential opportunity to improve health outcomes with early antiretroviral therapy (ART) [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/d/html/3717.html" rel="external">"Acute and early HIV infection: Treatment", section on 'Rationale for initiation of ART in early infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The HIV-1/HIV-2 differentiation assays determine if a patient is infected with HIV-1 or HIV-2 (or both). Although HIV-2 is less common than HIV-1 in the United States, accounting for less than 0.2 percent of cases, this distinction has important implications for HIV treatment [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/16252.html" rel="external">"Treatment of HIV-2 infection"</a>.)</p><p></p><p>Using this algorithm, an HIV screening program at a Phoenix, Arizona emergency department identified 37 undiagnosed HIV infections from July 2011 to February 2013. Of these, 12 (32.4 percent) were acute HIV infections [<a href="#rid42">42</a>]. Another prospective evaluation of this algorithm (the STOP study) diagnosed 610 previously undiagnosed HIV infections, of which 55 were consistent with acute infection. Applying this new HIV testing algorithm averted missed diagnoses in 32 percent of the HIV-infected patients in the Phoenix emergency department and 9 percent of those in the STOP study.</p><p>Testing algorithms used in resource-limited settings are described elsewhere in this topic. (See <a class="local">'Resource-limited settings'</a> below.)</p><p class="headingAnchor" id="H2637204764"><span class="h2">Alternative approaches</span><span class="headingEndMark"> — </span>Routine screening for HIV was and, in some laboratories, is still done by using a two-tiered approach via an initial enzyme-linked immunosorbent assay (ELISA) that only detects the presence of antibodies, followed by a confirmatory Western blot if the initial ELISA is positive. Although the accuracy of this testing algorithm for patients with chronic infection is extremely high (&gt;99 percent sensitivity and specificity), it can fail to diagnose individuals who are early in the course of their infection when antibody has not fully developed  (<a class="graphic graphic_table graphicRef87673" href="/d/graphic/87673.html" rel="external">table 1</a>). It can also misclassify HIV-2 infection, with approximately 60 percent of HIV-2 infections being misclassified as HIV-1 [<a href="#rid43">43</a>]. (See <a class="local">'Antibody-only tests'</a> below.)</p><p>Rapid point-of-care antibody screening tests are sometimes performed for convenience and/or cost [<a href="#rid44">44</a>]. An initial positive rapid antibody test is only preliminary. In this setting, a laboratory-based combination antigen/antibody assay should be performed if the rapid test is positive. Confirmatory testing (eg, HIV-1/HIV-2 antibody differentiation assay) is only needed if the combination immunoassay is positive [<a href="#rid37">37</a>]. (See <a class="local">'Screening tests'</a> below.)</p><p>As with the preferred testing algorithm described above, HIV RNA (either qualitative or quantitative) should be performed if there is concern for acute HIV infection. A detailed discussion of how to diagnose acute HIV infection is found elsewhere. (See  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3463981818"><span class="h2">Interpretation of results</span><span class="headingEndMark"> — </span>The results of serologic testing algorithms are reported as positive, negative, or indeterminate:</p><p class="bulletIndent1"><span class="glyph">●</span>The criteria for a positive test are a positive combination assay or ELISA followed by a positive confirmatory assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A negative test is a negative screening combination assay or ELISA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An indeterminate result is when the combination assay or ELISA is positive but the confirmatory test is indeterminate or negative.</p><p></p><p>Although rare, false negative and false positive test results can occur. They can be a result of patient-related factors (eg, lack or low level of HIV antibodies, cross-reactive antibodies due to a concurrent condition) or the test itself (eg, low sensitivity, failure to detect certain subtypes of HIV, laboratory error during testing) [<a href="#rid45">45-53</a>].</p><p>False-negative screening results are more likely to be seen with antibody-only ELISA tests than the combination antigen/antibody tests since most false-negative results are due to the window period after HIV acquisition before antibodies are detected (ie, acute infection). The use of combination antigen/antibody assays has reduced (but not eliminated) the likelihood of a false-negative result by the addition of the P24 antigen test  (<a class="graphic graphic_table graphicRef87673" href="/d/graphic/87673.html" rel="external">table 1</a>) [<a href="#rid54">54,55</a>]. (See <a class="local">'Screening tests'</a> below.)</p><p>The frequency of both the screening and confirmatory test yielding a false-positive test result is extremely rare, even in low-prevalence areas. As an example, the false-positive rate using a third-generation antibody test and a confirmatory Western blot ranges from 0.0004 to 0.0007 percent [<a href="#rid56">56-58</a>].</p><p class="headingAnchor" id="H1139383765"><span class="h2">Indeterminate test results</span></p><p class="headingAnchor" id="H2806265653"><span class="h3">Reasons for an indeterminate result</span><span class="headingEndMark"> — </span>Indeterminate test results occur when the initial screening test is positive (ie, third-generation ELISA or fourth-generation combination assay) and the confirmatory test is indeterminate or negative.</p><p>The most important HIV-related cause of an indeterminate test result is recently acquired infection. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A positive combination antigen/antibody test and a negative HIV differentiation assay may occur if the combination assay detects only p24 antigen. The subsequent HIV differentiation assay would be negative since it detects only antibody. (See <a class="local">'Combination HIV antigen and antibody tests'</a> below and <a class="local">'HIV-1/HIV-2 differentiation immunoassay'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A positive screening test (third-generation ELISA test or the combination antigen/antibody test) and a negative Western blot can be seen in acute infection since both types of screening tests can detect antibody before the Western blot meets criteria for being positive  (<a class="graphic graphic_table graphicRef87673" href="/d/graphic/87673.html" rel="external">table 1</a>). This scenario can also be seen in HIV-2 infection, since the screening assays test for HIV-1 and HIV-2, whereas the confirmatory Western blot only tests for HIV-1.</p><p></p><p>The predictive value of a reactive fourth-generation combination assay for acute infection after a negative confirmatory test is less than 10 percent in most situations because the prevalence of acute HIV is so low. As a result, in most clinical settings, a reactive fourth-generation test with a negative confirmatory test will not indicate HIV infection when further work-up is performed [<a href="#rid59">59</a>]. (See <a class="local">'Approach to an indeterminate result'</a> below.)</p><p>Reasons for a positive screening test resulting from factors not related to HIV infection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cross-reacting alloantibodies from pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Autoantibodies (collagen-vascular diseases, autoimmune diseases, and malignancy)</p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of an experimental HIV-1 vaccine [<a href="#rid60">60</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Influenza vaccination [<a href="#rid61">61</a>]</p><p></p><p class="headingAnchor" id="H603470239"><span class="h3">Approach to an indeterminate result</span><span class="headingEndMark"> — </span>We check a plasma HIV RNA in all patients with an indeterminate test result. For patients with a possible exposure to HIV-2, HIV-2-specific antibody and/or HIV-2 viral load testing should be performed if a Western blot was used as the confirmatory test. (See  <a class="medical medical_review" href="/d/html/16727.html" rel="external">"Clinical manifestations and diagnosis of HIV-2 infection", section on 'Testing for HIV-2 infection'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In general, a detectable HIV RNA is consistent with HIV infection and patients should be referred for appropriate care. Very rarely, a detectable HIV RNA at low levels (eg, &lt;1000 copies/mL) may represent a false-positive result due to the limitations of viral load testing. If this low-level result occurs, the viral load test should be repeated on a new blood specimen. The diagnosis of HIV infection is confirmed if the second virologic test is positive or a serologic test done several weeks later is fully reactive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the HIV RNA is negative, our approach depends upon the patient’s risk for HIV infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the HIV RNA is negative in a patient who is at low risk for HIV, he or she should be reassured that HIV infection is very unlikely. However, some providers repeat serologic testing approximately three months after the first test since patients do not always disclose their actual risk status. For most individuals, repeat testing remains indeterminate, often without a clear reason [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with a recent high-risk exposure (eg, unprotected anal sex, sharing needles), we repeat an HIV RNA in one to two weeks. We repeat virologic testing sooner if the patient develops symptoms of acute infection. (See  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p>Patients should be counseled to avoid activities that could transmit HIV (eg, unsafe sex, sharing needles, donating blood) until evaluation of the indeterminate test is complete. This is particularly true for individuals suspected of having acute HIV infection; given the elevated viral loads that are seen at this early stage of infection, these patients are at high risk of transmitting HIV to others. (See  <a class="medical medical_review" href="/d/html/3752.html" rel="external">"Acute and early HIV infection: Pathogenesis and epidemiology", section on 'Infectivity'</a>.)</p><p class="headingAnchor" id="H3828426"><span class="h1">TESTS</span><span class="headingEndMark"> — </span>Available tests for the diagnosis of HIV infection include those that can detect:</p><p class="bulletIndent1"><span class="glyph">●</span>HIV antibody (enzyme-linked immunosorbent assays [ELISAs], HIV -1/HIV-2 differentiation assays, Western blot)</p><p class="bulletIndent1"><span class="glyph">●</span>HIV antibody and HIV antigen</p><p class="bulletIndent1"><span class="glyph">●</span>HIV antigen</p><p class="bulletIndent1"><span class="glyph">●</span>HIV RNA (qualitative or quantitative)</p><p></p><p>The ability of these tests to detect HIV-1 and HIV-2, as well as certain groups of HIV (eg, M, N, O, and P), depends upon the type of test that is used.</p><p>The different tests for HIV are discussed in this section. Our suggested approach for screening/diagnosis of HIV infection (ie, testing algorithm) is presented above. (See <a class="local">'Testing algorithm'</a> above.)</p><p class="headingAnchor" id="H3246901088"><span class="h2">Screening tests</span></p><p class="headingAnchor" id="H3991496213"><span class="h3">Antibody-only tests</span><span class="headingEndMark"> — </span>ELISAs that detect antibody to HIV are used as an initial test to screen for HIV infection. These tests (referred to as a third-generation antibody test when detecting immunoglobulin M [IgM] as well as IgG antibodies) detect the presence of HIV-1 and HIV-2 antibody as early as three weeks after exposure to the virus  (<a class="graphic graphic_table graphicRef87673" href="/d/graphic/87673.html" rel="external">table 1</a>). The ELISA antibody tests in the United States and Europe detect all M subtypes but do not consistently detect other groups [<a href="#rid45">45,46,63,64</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory-based tests</strong> – Certain ELISA tests are only designed to be performed in the laboratory. While some provide results in less than an hour, others require a longer turnaround time (&gt;3 hours) [<a href="#rid65">65</a>]. The sensitivity and specificity of these tests approaches 100 percent for diagnosing chronic infection. Although these tests are not as sensitive as combination antigen/antibody tests for diagnosing acute infection, they are more sensitive than rapid antibody tests. A positive laboratory-based test should be confirmed with either an HIV-1/HIV-2 differentiation assay or, if unavailable, an HIV Western blot. (See <a class="local">'HIV-1/HIV-2 differentiation immunoassay'</a> below and <a class="local">'Western blot'</a> below and <a class="local">'Combination HIV antigen and antibody tests'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid tests</strong> – Rapid screening tests are designed to provide results in less than 20 minutes. Although these tests can be performed in the laboratory (using serum or plasma), they can also be performed in community-based settings supervised by trained personnel, or at home, using whole blood or oral secretions. Rapid tests have the advantage of offering preliminary test results at the same patient encounter, and are they well suited for patients who obtain sporadic medical care and for patients who are unlikely to return for their results [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">The accuracy of most rapid tests is quite high (&gt;99 percent sensitivity and specificity) for patients with chronic infection. However, in one study, rapid antibody tests missed approximately 12 percent of acute HIV infections [<a href="#rid54">54</a>]. In addition, testing on oral fluids appears to be less sensitive than testing on finger stick blood samples [<a href="#rid67">67</a>]. In a retrospective observational study of the use of oral fluid testing in detecting HIV seroconversion, 233 false-negative results occurred in 80 of 287 individuals [<a href="#rid68">68</a>]. According to the Centers for Disease Control and Prevention (CDC), up to 8 percent of HIV-infected people can have a false-negative result when oral in-home tests are used [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H679394082"><span class="h3">Combination HIV antigen and antibody tests</span><span class="headingEndMark"> — </span>Fourth-generation HIV tests are distinguished from antibody-only tests by their ability to detect both HIV antibody and HIV p24 antigen [<a href="#rid70">70-72</a>]. Combined HIV antigen/antibody tests can detect HIV-1 and HIV-2 as well as group M and group O infections [<a href="#rid47">47,48</a>].</p><p>The sensitivity and specificity of the fourth-generation tests approach 100 percent for patients with chronic HIV infection. In addition, these tests are able to identify acute/early infection in up to 80 percent of patients whose HIV diagnosis would have been missed by antibody-only testing, although they are not as sensitive as HIV RNA testing. As an example, in a prospective study of 86,836 patients recruited from 12 sexually transmitted infection and community-based clinics in the United States, those who tested negative for HIV using a rapid antibody test were then screened for HIV infection with a fourth-generation laboratory-based combination HIV assay and pooled HIV RNA testing [<a href="#rid54">54</a>]. Among the 85,690 patients who had a negative rapid antibody test, 168 patients were found to have acute HIV infection; the combination antibody and antigen test detected 134 (82 percent) of those that were detected by HIV RNA testing.</p><p>Three of the available combination tests in the United States are designed to provide rapid results (ie, within 30 minutes):</p><p class="bulletIndent1"><span class="glyph">●</span>The ARCHITECT HIV Ag/Ab Combo test is an immunoassay that is designed to be performed in the laboratory. It can be used to analyze batches of specimens or to provide rapid results on a single sample.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Elecsys HIV Duo test is another immunoassay designed to be performed in the laboratory. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Determine HIV 1/2 Ag/Ab Combo provides rapid results using lateral flow technology on a single specimen.</p><p></p><p>Although the Determine HIV 1/2 Ag/Ab Combo test is well suited for point-of-care settings, laboratory-based combination tests that use an immunoassay are more sensitive and are better for diagnosing acute infection [<a href="#rid72">72-75</a>]. Studies that illustrate these findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 21,234 consecutive venous blood samples obtained by San Francisco HIV testing programs from 2003 to 2008, the ARCHITECT HIV Ag/Ab Combo fourth-generation immunoassay identified 87 percent of acute HIV infections, whereas the Determine HIV1/2 Ag-Ab Combo test, using lateral flow technology, detected 54 percent of acute infections [<a href="#rid76">76</a>]. However, both combination assays detected more acute infections compared with antibody-only tests, which only detected 26 to 35 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study evaluated the ability of the Determine Combo test to detect acute and/or early HIV-1 infection compared with other HIV tests [<a href="#rid73">73</a>]. The Determine Combo test was reactive approximately 15 to 16 days before a Western blot was positive and about two days before antibody-only tests were positive. However, the Determine Combo test was positive three to four days <strong>after</strong> a test that used technology similar to the ARCHITECT Combo test.</p><p></p><p class="headingAnchor" id="H2085025840"><span class="h2">Confirmatory tests</span></p><p class="headingAnchor" id="H2289391304"><span class="h3">HIV-1/HIV-2 differentiation immunoassay</span><span class="headingEndMark"> — </span>The HIV-1/HIV-2 differentiation assay is a rapid laboratory-based test that is typically used to confirm a positive fourth-generation combination assay and to distinguish between HIV-1 and HIV-2 infection. The turnaround time for this confirmatory test is generally &lt;20 minutes. This test is used as part of the preferred testing algorithm described above  (<a class="graphic graphic_algorithm graphicRef91270" href="/d/graphic/91270.html" rel="external">algorithm 1</a>). (See <a class="local">'Preferred approach'</a> above.)</p><p>Available HIV-1/HIV-2 differentiation tests include:</p><p class="bulletIndent1"><span class="glyph">●</span>The Bio-Rad Geenius HIV1/2 confirmation assay</p><p class="bulletIndent1"><span class="glyph">●</span>The Bio-Rad Multispot HIV-1/HIV-2</p><p></p><p>Both the Geenius and Multispot tests have high sensitivity for established infection (99.3 to 100 percent) [<a href="#rid77">77,78</a>]. The Multispot test is reported to have a specificity of 99.9 percent, whereas the Geenius test has a 4.3 percent indeterminate rate for low-risk populations [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H2511320745"><span class="h3">Western blot</span><span class="headingEndMark"> — </span>An HIV-1/HIV-2 differentiation assay is now the preferred confirmatory test. However, for many years, a confirmatory HIV-1 Western blot test was performed if an ELISA was positive to exclude the possibility of a false-positive screening test. The Western blot results usually took several days to weeks to return, as some clinic and hospital labs referred blood specimens for Western blot testing to reference labs. (See <a class="local">'Alternative approaches'</a> above.)</p><p>The Western blot detects IgG antibody to HIV-1; however, it can take up to two months after HIV acquisition for the test to turn fully positive. In addition, HIV-1 Western blot assays do not reliably detect subtype O virus [<a href="#rid45">45,63</a>], and if HIV-2 is being considered, a special HIV-2 Western blot must be requested. (See  <a class="medical medical_review" href="/d/html/16727.html" rel="external">"Clinical manifestations and diagnosis of HIV-2 infection", section on 'Diagnostic issues related to HIV-1 Western blot testing'</a>.)</p><p class="headingAnchor" id="H1133414348"><span class="h2">Viral detection</span><span class="headingEndMark"> — </span>Viral detection is an alternative approach to establishing an HIV diagnosis since virus is present in blood samples before HIV antibodies can be detected  (<a class="graphic graphic_table graphicRef87673" href="/d/graphic/87673.html" rel="external">table 1</a>). The most commonly used methods detect HIV RNA or HIV p24 antigen. The P subgroup of HIV can only be detected with nucleotide sequencing [<a href="#rid49">49</a>]</p><p>Testing for plasma HIV RNA is <strong>not</strong> considered superior to routine serologic testing in most situations. However, the use of viral detection as a diagnostic assay is indicated for:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of neonatal HIV infection (see  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation of patients with an indeterminate serologic test (see <a class="local">'Indeterminate test results'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation of suspected acute infection in someone who may be in the "window period" of HIV seroconversion (see  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Screening of blood donors (see  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'HIV-1 and HIV-2'</a>)</p><p></p><p>Plasma HIV RNA can be measured using qualitative or quantitative techniques. Qualitative testing (commonly referred to as nucleic acid testing [NAT]) is primarily used as a screening test to identify HIV-infected individuals, such as possible blood donors. Although quantification of HIV-RNA (viral load measurements) is designed primarily for use in the management and monitoring of HIV-1 infected individuals, this test is frequently utilized as a diagnostic test in suspected acute HIV infection since most clinicians have more ready access to quantitative viral load tests than NAT. (See  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'HIV-1 and HIV-2'</a> and  <a class="medical medical_review" href="/d/html/3743.html" rel="external">"Techniques and interpretation of HIV-1 RNA quantitation"</a> and  <a class="medical medical_review" href="/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'Virologic response'</a>.)</p><p>Detection of HIV p24 antigen is another method for detecting virus. The p24 antigen usually becomes detectable at about one to two weeks after viral transmission [<a href="#rid79">79</a>]. This test is less expensive than nucleic acid sequence-based testing and can identify approximately 80 to 90 percent of individuals who seek testing during acute infection [<a href="#rid80">80,81</a>]. Although current p24 antigen tests are more sensitive than early generations of this assay, they have predominantly been replaced by HIV RNA testing. The most common use of p24 antigen testing now is as part of the fourth-generation combined antibody/antigen test. (See  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'HIV antigen detection'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">PATIENT-RELATED ISSUES</span></p><p class="headingAnchor" id="H25116806"><span class="h2">Consent</span><span class="headingEndMark"> — </span>Screening should be voluntary and undertaken only with the patient's knowledge and understanding that HIV testing is being planned [<a href="#rid16">16,20</a>]. In most countries, a separate written consent for HIV testing is not required. In the United States, individual states have specific policies regarding the consenting process; however, no state still requires written consent by law. Information can be obtained at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fhiv%2Fpolicies%2Flaw%2Fstates%2Findex.html&amp;token=mjmpv7xMHRIW2nr%2B3NCnsf4ibzRkfx1fSXe8v7dJvRdRq%2BnoQcUKpvkFl%2BjAtmzTjcifBTMgfe4z0tklK00Ggw%3D%3D&amp;TOPIC_ID=3736" target="_blank">Centers for Disease Control and Prevention</a> (CDC) [<a href="#rid82">82</a>] and on the National Association of State and Territorial AIDS Directors (NASTAD) <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.nastad.org%2F&amp;token=gdEMl%2F3RV4q6xsBHuH4h8tCDYBil5uchU%2Ffg5AipYEQ%3D&amp;TOPIC_ID=3736" target="_blank">website</a>.</p><p>In some settings, routine testing is implemented through a strategy called "opt-out testing" whereby the patient is informed orally, or in writing, that HIV testing will be performed [<a href="#rid20">20</a>]. The patient may then elect to decline or defer testing. If the patient opts out, this is then recorded in the medical record. The use of "opt-out" testing is routinely done in the United Kingdom, and one study reported an increased percentage of individuals being tested (from 35 to 65 percent) after this approach was introduced [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Counseling</span><span class="headingEndMark"> — </span>Patients should be counseled regarding harm reduction, such as clean needle use by injection drug users or the use of barrier protection in those who have multiple sex partners. Persons with an indeterminate or positive HIV screening test need to be counseled that additional testing is required; however, in the interim, precautions should be taken to decrease transmission to others. An overview of HIV prevention strategies is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Clinical approach to HIV prevention'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Confidentiality</span><span class="headingEndMark"> — </span>Institution of routine HIV screening programs must be accompanied by scrupulous attention to patient confidentiality and appropriate counseling for post-test results [<a href="#rid84">84</a>]. Respect for patient confidentiality is necessary to minimize discrimination in insurance, employment, health care, and personal relationships, especially if someone tests positive for HIV.</p><p class="headingAnchor" id="H1133414954"><span class="h2">Referral to care</span><span class="headingEndMark"> — </span>If a patient is diagnosed with HIV infection, it is important to refer the patient for appropriate medical care. The CDC estimates that only 30 percent of the more than one million individuals in the United States who are living with HIV/AIDS are getting the full benefits of the treatment they need to manage their disease and keep the virus under control [<a href="#rid85">85</a>]. This estimate is based on surveillance data from 2011 that estimates for every 100 individuals living with HIV in the United States, 86 are aware of their HIV status, 40 are engaged in HIV care, 37 are prescribed antiretroviral therapy (ART), and 30 are able to adhere to their treatment and sustain undetectable viral loads.</p><p>One modelling study suggests strategies that combine enhanced testing and linkage with improved retention would reduce the HIV incidence by 54 percent and the mortality rate by 64 percent [<a href="#rid86">86</a>]. In San Francisco, a program that initiated ART as soon as possible after diagnosis was evaluated in a cohort of 39 patients with acute or recent infection (&lt;6 months) or a CD4 count &lt;200 cells/microL [<a href="#rid87">87</a>]. Approximately 95 percent initiated ART within 24 hours of diagnosis, and almost all received a regimen that included an integrase strand transfer inhibitor. The median time to achieve an HIV RNA &lt;200 copies/mL was significantly faster among those who received the intervention compared with a cohort of 116 patients who received standard of care (1.8 versus 4.3 months). However, loss to follow-up was similar between the groups. Continued efforts are needed to improve all aspects of this treatment cascade.</p><p class="headingAnchor" id="H114330379"><span class="h1">RESOURCE-LIMITED SETTINGS</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) has issued recommendations for HIV testing in low- and middle-income countries [<a href="#rid88">88</a>]. Detailed information can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F978-92-4-155058-1&amp;token=xyCp31wavFlytWxBy%2FtjD2gdnW2VzebB5jUtdarOFZZXkrH9uhkXdSANbPxSu7OXtXLosBfSh4%2BtzzyQZkA%2Fia8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=3736" target="_blank">WHO website</a>. All testing must be voluntary and confidential. HIV testing efforts should also provide links to prevention, care, and treatment services. (See <a class="local">'Patient-related issues'</a> above.)</p><p class="headingAnchor" id="H3825298897"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111622.html" rel="external">"Society guideline links: HIV screening and diagnostic testing"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15448.html" rel="external">"Patient education: HIV/AIDS (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/3697.html" rel="external">"Patient education: Testing for HIV (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/3695.html" rel="external">"Patient education: Symptoms of HIV (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Nearly 15 percent of HIV-infected persons in the United States remain unaware of their HIV infection. Improved access to HIV testing and new testing algorithms can decrease the number of individuals who present with advanced immunocompromise, enhance the detection of newly infected individuals, and reduce transmission to others. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV testing should be performed to diagnose HIV infection in patients with clinical signs and symptoms of acute or chronic infection, as well as those with a possible exposure to HIV. (See <a class="local">'Symptoms of HIV infection'</a> above and <a class="local">'Possible HIV exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients without identifiable risk factors for HIV acquisition, we recommend one-time HIV screening in adults and adolescents 13 to 75 years of age rather than risk-based screening (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). HIV testing should also be performed for all pregnant women, even if they have been screened during previous pregnancies. (See <a class="local">'Routine screening'</a> above and <a class="local">'Rationale for routine screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with ongoing high-risk behaviors (eg, men who have sex with men with sexual partners who are HIV-infected or have unknown serostatus, injection-drug users, persons who exchange sex for money or drugs, sex partners of persons who are HIV-infected) annual or more frequent screening should be performed. (See <a class="local">'Routine screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For routine HIV screening and diagnosis, we use a fourth-generation combination HIV-1/2 immunoassay that detects HIV p24 antigen <strong>and</strong> HIV antibodies; if positive, a confirmatory HIV-1/HIV-2 antibody differentiation immunoassay should be performed  (<a class="graphic graphic_algorithm graphicRef91270" href="/d/graphic/91270.html" rel="external">algorithm 1</a>). The combination antigen/antibody tests are better able to identify acute/early infection compared with antibody-only tests, since they can detect HIV p24 antigen at a time when antibody may not yet be present. (See <a class="local">'Preferred approach'</a> above and <a class="local">'Tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is concern for acute HIV infection (eg, the patient presents with mononucleosis-like symptoms and had a recent high-risk exposure), additional testing with HIV RNA (either qualitative or quantitative) should be performed. (See  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indeterminate test results occur when the initial screening test is positive (ie, third-generation antibody assay or fourth-generation combination assay) and the confirmatory test (HIV-1/HIV-2 differentiation assay or Western blot) is indeterminate or negative. An indeterminate test may result from recently acquired HIV infection or be the result of a false positive screening test. Plasma HIV RNA should be tested in all patients with an indeterminate test result. (See <a class="local">'Indeterminate test results'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). HIV testing among men who have sex with men--21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 2011; 60:694.</a></li><li><a class="nounderline abstract_t">DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV Screening of Gay, Bisexual, and Other Men Who Have Sex with Men - United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:830.</a></li><li><a class="nounderline abstract_t">Frieden TR, Foti KE, Mermin J. Applying Public Health Principles to the HIV Epidemic--How Are We Doing? N Engl J Med 2015; 373:2281.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Previous HIV testing among adults and adolescents newly diagnosed with HIV infection - National HIV Surveillance System, 18 jurisdictions, United States, 2006-2009. MMWR Morb Mortal Wkly Rep 2012; 61:441.</a></li><li><a class="nounderline abstract_t">Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11.</a></li><li><a class="nounderline abstract_t">Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14:281.</a></li><li><a class="nounderline abstract_t">TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808.</a></li><li><a class="nounderline abstract_t">INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795.</a></li><li><a class="nounderline abstract_t">Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.</a></li><li><a class="nounderline abstract_t">Marcus JL, Chao CR, Leyden WA, et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr 2016; 73:39.</a></li><li class="breakAll">Centers for Disease Control and Prevention. HIV surveillance report. Diagnosis of HIV infection and AIDS in the United States and dependent areas, 2009. http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/pdf/2009SurveillanceReport.pdf.</li><li><a class="nounderline abstract_t">Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49:1570.</a></li><li><a class="nounderline abstract_t">Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.</a></li><li><a class="nounderline abstract_t">Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447.</a></li><li class="breakAll">World Health Organization.Consolidated guidelines on HIV testing services. July 2015 http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926_eng.pdf?ua=1&amp;ua=1.</li><li class="breakAll">United States Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States 2010–2015. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-23-1.pdf (Accessed on July 12, 2018).</li><li><a class="nounderline abstract_t">Hall HI, An Q, Tang T, et al. Prevalence of Diagnosed and Undiagnosed HIV Infection--United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2015; 64:657.</a></li><li><a class="nounderline abstract_t">Wejnert C, Prejean J, Hoots B, et al. Prevalence of Missed Opportunities for HIV Testing Among Persons Unaware of Their Infection. JAMA 2018; 319:2555.</a></li><li><a class="nounderline abstract_t">Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Klein D, Hurley LB, Merrill D, et al. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003; 32:143.</a></li><li><a class="nounderline abstract_t">Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med 2009; 150:125.</a></li><li><a class="nounderline abstract_t">Moyer VA, U.S. Preventive Services Task Force*. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013; 159:51.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA 2019; 321:2326.</a></li><li><a class="nounderline abstract_t">Hutchinson AB, Farnham PG, Duffy N, et al. Return on public health investment: CDC's Expanded HIV Testing Initiative. J Acquir Immune Defic Syndr 2012; 59:281.</a></li><li><a class="nounderline abstract_t">Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med 2005; 352:586.</a></li><li><a class="nounderline abstract_t">Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570.</a></li><li><a class="nounderline abstract_t">Walensky RP, Weinstein MC, Kimmel AD, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med 2005; 118:292.</a></li><li><a class="nounderline abstract_t">Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145:797.</a></li><li><a class="nounderline abstract_t">Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 2010; 153:778.</a></li><li><a class="nounderline abstract_t">Branson BM. To screen or not to screen: is that really the question? Ann Intern Med 2006; 145:857.</a></li><li><a class="nounderline abstract_t">Lyons MS, Lindsell CJ, Ruffner AH, et al. Randomized comparison of universal and targeted HIV screening in the emergency department. J Acquir Immune Defic Syndr 2013; 64:315.</a></li><li><a class="nounderline abstract_t">Leber W, McMullen H, Anderson J, et al. Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial. Lancet HIV 2015; 2:e229.</a></li><li><a class="nounderline abstract_t">Castel AD, Greenberg AE, Befus M, et al. Temporal association between expanded HIV testing and improvements in population-based HIV/AIDS clinical outcomes, District of Columbia. AIDS Care 2014; 26:785.</a></li><li><a class="nounderline abstract_t">Myers JE, Braunstein SL, Shepard CW, et al. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. J Acquir Immune Defic Syndr 2012; 61:23.</a></li><li><a class="nounderline abstract_t">Suthar AB, Ford N, Bachanas PJ, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med 2013; 10:e1001496.</a></li><li class="breakAll">Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention. Available at: https://stacks.cdc.gov/view/cdc/23447. (Accessed on January 26, 2023).</li><li><a class="nounderline abstract_t">Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: a review of current methods. Clin Infect Dis 2013; 57:712.</a></li><li><a class="nounderline abstract_t">Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr 2013; 63 Suppl 2:S187.</a></li><li><a class="nounderline abstract_t">Nasrullah M, Wesolowski LG, Meyer WA 3rd, et al. Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS 2013; 27:731.</a></li><li><a class="nounderline abstract_t">Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000-2008. Clin Infect Dis 2010; 51:1334.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013; 62:489.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). HIV-2 Infection Surveillance--United States, 1987-2009. MMWR Morb Mortal Wkly Rep 2011; 60:985.</a></li><li><a class="nounderline abstract_t">Hoenigl M, Graff-Zivin J, Little SJ. Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms. Clin Infect Dis 2016; 62:501.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Identification of HIV-1 group O infection--Los Angeles county, California, 1996. MMWR Morb Mortal Wkly Rep 1996; 45:561.</a></li><li><a class="nounderline abstract_t">Zouhair S, Roussin-Bretagne S, Moreau A, et al. Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J Clin Microbiol 2006; 44:662.</a></li><li><a class="nounderline abstract_t">Weber B, Orazi B, Raineri A, et al. Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi. Clin Lab 2006; 52:463.</a></li><li><a class="nounderline abstract_t">Yeom JS, Jun G, Chang Y, et al. Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the LG HIV Ag-Ab Plus, with a combined HIV p24 antigen and anti-HIV-1/2/O screening test. J Virol Methods 2006; 137:292.</a></li><li><a class="nounderline abstract_t">Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15:871.</a></li><li><a class="nounderline abstract_t">Farzadegan H, Polis MA, Wolinsky SM, et al. Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1988; 108:785.</a></li><li><a class="nounderline abstract_t">Spivak AM, Sydnor ER, Blankson JN, Gallant JE. Seronegative HIV-1 infection: a review of the literature. AIDS 2010; 24:1407.</a></li><li><a class="nounderline abstract_t">Ellenberger DL, Sullivan PS, Dorn J, et al. Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons. J Infect Dis 1999; 180:1033.</a></li><li><a class="nounderline abstract_t">Liu P, Jackson P, Shaw N, Heysell S. Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests. AIDS Res Ther 2016; 13:1.</a></li><li><a class="nounderline abstract_t">Peters PJ, Westheimer E, Cohen S, et al. Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population. JAMA 2016; 315:682.</a></li><li><a class="nounderline abstract_t">Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis 2012; 205:521.</a></li><li><a class="nounderline abstract_t">Burke DS, Brundage JF, Redfield RR, et al. Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med 1988; 319:961.</a></li><li><a class="nounderline abstract_t">MacDonald KL, Jackson JB, Bowman RJ, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med 1989; 110:617.</a></li><li><a class="nounderline abstract_t">Kleinman S, Busch MP, Hall L, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA 1998; 280:1080.</a></li><li class="breakAll">Sax PE, The Most Common Question About the New HIV Testing Algorithm, Answered. HIV and ID Observations. http://blogs.jwatch.org/hiv-id-observations/index.php/new-hiv-testing-algorithm-great-not-perfect-nothing/2016/09/04/http://blogs.jwatch.org/hiv-id-observations/index.php/new-hiv-testing-algorithm-great-not-perfect-nothing/2016/09/04/ (Accessed on September 08, 2016).</li><li><a class="nounderline abstract_t">Cooper CJ, Metch B, Dragavon J, et al. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010; 304:275.</a></li><li><a class="nounderline abstract_t">Erickson CP, McNiff T, Klausner JD. Influenza vaccination and false positive HIV results. N Engl J Med 2006; 354:1422.</a></li><li><a class="nounderline abstract_t">Jackson JB, MacDonald KL, Cadwell J, et al. Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. N Engl J Med 1990; 322:217.</a></li><li><a class="nounderline abstract_t">Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393.</a></li><li><a class="nounderline abstract_t">Schable C, Zekeng L, Pau CP, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994; 344:1333.</a></li><li class="breakAll">The United States Centers for Disease Control and Prevention. Advantages and disadvantages of FDA-approved HIV immunoassays used for screening by test format and CLIA complexity. http://www.cdc.gov/hiv/pdf/testing/hiv-tests-advantages-disadvantages.pdf (Accessed on October 28, 2015).</li><li><a class="nounderline abstract_t">Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:390.</a></li><li><a class="nounderline abstract_t">Jaspard M, Le Moal G, Saberan-Roncato M, et al. Finger-stick whole blood HIV-1/-2 home-use tests are more sensitive than oral fluid-based in-home HIV tests. PLoS One 2014; 9:e101148.</a></li><li><a class="nounderline abstract_t">Curlin ME, Gvetadze R, Leelawiwat W, et al. Analysis of False-Negative Human Immunodeficiency Virus Rapid Tests Performed on Oral Fluid in 3 International Clinical Research Studies. Clin Infect Dis 2017; 64:1663.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Home tests. http://www.cdc.gov/hiv/testing/hometests.html (Accessed on May 02, 2016).</li><li><a class="nounderline abstract_t">Malm K, von Sydow M, Andersson S. Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples. Transfus Med 2009; 19:78.</a></li><li class="breakAll">Centers for Disease Control and Prevention. FDA-approved HIV screening tests for laboratory use only. http://www.cdc.gov/hiv/pdf/testing/hiv-tests-laboratory-use.pdf (Accessed on October 27, 2015).</li><li class="breakAll">Centers for Disease Control and Prevention. Alere Determine HIV-1/2 Ag/Ab combo information sheet for testing programs. http://www.cdc.gov/hiv/pdf/testing/hiv-tests-laboratory-use.pdf (Accessed on December 16, 2014).</li><li><a class="nounderline abstract_t">Masciotra S, Luo W, Youngpairoj AS, et al. Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol 2013; 58 Suppl 1:e54.</a></li><li><a class="nounderline abstract_t">Duong YT, Mavengere Y, Patel H, et al. Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland. J Clin Microbiol 2014; 52:3743.</a></li><li><a class="nounderline abstract_t">Conway DP, Holt M, McNulty A, et al. Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population. PLoS One 2014; 9:e94062.</a></li><li><a class="nounderline abstract_t">Pilcher CD, Louie B, Facente S, et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One 2013; 8:e80629.</a></li><li><a class="nounderline abstract_t">Malloch L, Kadivar K, Putz J, et al. Comparative evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an alternative differentiation assay for CLSI M53 algorithm-I. J Clin Virol 2013; 58 Suppl 1:e85.</a></li><li class="breakAll">Centers for Disease Control and Prevention. FDA-Approved HIV supplemental tests for laboratory use only. http://www.cdc.gov/hiv/pdf/testing/supplemental-hiv-tests-laboratory-use.pdf (Accessed on October 05, 2015).</li><li><a class="nounderline abstract_t">Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871.</a></li><li><a class="nounderline abstract_t">Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25.</a></li><li><a class="nounderline abstract_t">Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007; 195:416.</a></li><li class="breakAll">http://www.cdc.gov/hiv/policies/law/states/index.html (Accessed on March 01, 2016).</li><li><a class="nounderline abstract_t">Stanley B, Fraser J, Cox NH. Uptake of HIV screening in genitourinary medicine after change to "opt-out" consent. BMJ 2003; 326:1174.</a></li><li><a class="nounderline abstract_t">Bozzette SA. Routine screening for HIV infection--timely and cost-effective. N Engl J Med 2005; 352:620.</a></li><li><a class="nounderline abstract_t">Bradley H, Hall HI, Wolitski RJ, et al. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep 2014; 63:1113.</a></li><li><a class="nounderline abstract_t">Shah M, Risher K, Berry SA, Dowdy DW. The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. Clin Infect Dis 2016; 62:220.</a></li><li><a class="nounderline abstract_t">Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr 2017; 74:44.</a></li><li class="breakAll">World Health Organization. Consolidated guidelines on HIV testing services. https://www.who.int/publications/i/item/978-92-4-155058-1 (Accessed on May 27, 2021).</li></ol></div><div id="topicVersionRevision">Topic 3736 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sexually transmitted diseases treatment guidelines, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21637183" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : HIV testing among men who have sex with men--21 cities, United States, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796758" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recommendations for HIV Screening of Gay, Bisexual, and Other Men Who Have Sex with Men - United States, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26624243" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Applying Public Health Principles to the HIV Epidemic--How Are We Doing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22717512" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Previous HIV testing among adults and adolescents newly diagnosed with HIV infection - National HIV Surveillance System, 18 jurisdictions, United States, 2006-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16741877" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The survival benefits of AIDS treatment in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602844" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26193126" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192873" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24367482" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028501" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028501" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845472" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767103" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevention of HIV-1 infection with early antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791020" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791020" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791020" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26110835" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of Diagnosed and Undiagnosed HIV Infection--United States, 2008-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946714" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of Missed Opportunities for HIV Testing Among Persons Unaware of Their Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988643" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12571523" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047022" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698354" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31184701" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067662" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Return on public health investment: CDC's Expanded HIV Testing Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703423" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Expanded screening for HIV in the United States--an analysis of cost-effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703422" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745728" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146064" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21173412" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146069" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : To screen or not to screen: is that really the question?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846569" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized comparison of universal and targeted HIV screening in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423195" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24206005" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Temporal association between expanded HIV testing and improvements in population-based HIV/AIDS clinical outcomes, District of Columbia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22739134" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966838" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966838" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23667267" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Laboratory diagnosis of HIV in adults: a review of current methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764635" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The detection and management of early HIV infection: a clinical and public health emergency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135170" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039219" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : HIV type 2 in New York City, 2000-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784012" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796096" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : HIV-2 Infection Surveillance--United States, 1987-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26508512" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9132574" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Identification of HIV-1 group O infection--Los Angeles county, California, 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455942" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17078473" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908076" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the LG HIV Ag-Ab Plus, with a combined HIV p24 antigen and anti-HIV-1/2/O screening test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648927" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A new human immunodeficiency virus derived from gorillas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285743" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20467287" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Seronegative HIV-1 infection: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10479128" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26734067" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26881371" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207652" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Detection of acute HIV infection: we can't close the window.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3419477" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Measurement of the false positive rate in a screening program for human immunodeficiency virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2648922" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9757856" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9757856" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639561" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571889" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Influenza vaccination and false positive HIV results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403658" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910884" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7968029" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7968029" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038358" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24971842" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Finger-stick whole blood HIV-1/-2 home-use tests are more sensitive than oral fluid-based in-home HIV tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369309" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Analysis of False-Negative Human Immunodeficiency Virus Rapid Tests Performed on Oral Fluid in 3 International Clinical Research Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369309" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Analysis of False-Negative Human Immunodeficiency Virus Rapid Tests Performed on Oral Fluid in 3 International Clinical Research Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320855" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320855" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320855" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23911678" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Performance of the Alere Determine™HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25122853" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24714441" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24349007" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24342484" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparative evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an alternative differentiation assay for CLSI M53 algorithm-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24342484" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparative evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an alternative differentiation assay for CLSI M53 algorithm-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960819" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187417" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205481" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rapid, real-time detection of acute HIV infection in patients in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205481" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rapid, real-time detection of acute HIV infection in patients in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775616" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Uptake of HIV screening in genitourinary medicine after change to "opt-out" consent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703428" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Routine screening for HIV infection--timely and cost-effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25426654" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26362321" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434707" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
